MannKind Corporation (MNKD)
Most of the food people eat is broken down into glucose, the form of sugar in the blood. Glucose is vital to your health because it's an important source of energy for the cells that make up your muscles and tissues. It's also your brain's main source of fuel.
Diabetes is a chronic disease that occurs either when the pancreas does not produce enough insulin or when the body cannot effectively use the insulin it produces. Insulin is a hormone that is needed to convert sugar, starches and other food into energy needed for daily life.
Type 1 diabetes (previously known as insulin-dependent, juvenile or childhood-onset) is characterized by deficient insulin production. A person who has type 1 diabetes must take insulin daily to live.
Type 2 diabetes (formerly called non-insulin-dependent or adult-onset) results from the body’s ineffective use of insulin. It comprises 90% of people with diabetes around the world, and is largely the result of excess body weight and physical inactivity. In type 2 diabetes, either the body does not produce enough insulin or the cells ignore the insulin.
Gestational diabetes is hyperglycaemia with onset or first recognition during pregnancy. Hyperglycaemia, or raised blood sugar, is a common effect of uncontrolled diabetes.
Over time, diabetes can damage the heart, blood vessels, eyes, kidneys, and nerves.
MNKD reported that the FDA's Endocrinologic and Metabolic Drugs Advisory Committee voted 13 to 1 to recommend that AFREZZA(R) (insulin human [rDNA origin]) Inhalation Powder be granted marketing approval by the FDA to improve glycemic control in adults with type 1 diabetes and voted 14 to 0 to recommend that AFREZZA be granted marketing approval by the FDA to improve glycemic control in adults with type 2 diabetes.
If approved, AFREZZA would be the first ultra rapid-acting mealtime insulin therapy available in the United States.
AFREZZA(R) is a novel, ultra rapid-acting mealtime insulin therapy developed by MNKD to improve glycemic control in adult patients with type 1 or type 2 diabetes. It is a drug-device combination product, consisting of AFREZZA Inhalation Powder delivered using a small, discreet and easy-to-use inhaler.
Administered at the start of a meal, AFREZZA Inhalation Powder dissolves immediately upon inhalation to the deep lung and delivers insulin quickly to the bloodstream. Peak insulin levels are achieved within 12 to 15 minutes of administration, compared to 45-90 minutes for injected rapid acting insulin analogs and 90-150 minutes for injected regular human insulin.
MNKD focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes.
More about MannKind Corporation (MNKD) at www.mannkindcorp.com .
**
Crown Equity Holdings Inc. (CRWE)
CRWE is currently developing its CRWE Network ( CRWE-PR.com ), a social networking service compatible with both, the mobile and desktop web platform, that is designed to target all the communities in the U.S. and Canada.
Update: The CRWE Network, which business model is based on selling advertising to local businesses, has reached the 311th community website in the U.S., associated with 1511 ZIP Codes , and includes coverage of the greater state of California, Northern and Southern Nevada, Wellington in Florida and 9 provinces in Canada
CRWE provides marketing solutions that boost customer awareness and merchant visibility on the Internet.
More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com
**
Autobytel Inc. (ABTL)
Keep a close eye on ABTL . The company has raised its revenue guidance for the first quarter of 2014.
ABTL expects total revenue growth , including the contribution from its recently completed acquisition of AutoUSA, of 45% to 47% for the first quarter of 2014 , compared to the same period the prior year. ABTL also now expects organic revenue growth, excluding the contribution from AutoUSA, in the range of 22% to 24% for the first quarter ended March 31, 2014, compared with last year.
** ABTL 's original guidance range called for revenue growth of 18% to 22% **
Additionally, ABTL expects earnings per diluted share (EPS) of approximately $0.03 for the 2014 first quarter, in line with analysts' estimates.
ABTL provides high quality consumer leads and associated marketing services to automotive dealers and manufacturers throughout the United States and offers consumers robust and original online automotive content to help them make informed car-buying decisions.
More about Autobytel Inc. (ABTL) at www.autobytel.com
**
Read Full Disclaimer at www.pennyomega.com/disclaimer
